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Abstract 
Infection is an inevitable consequence of chronic urinary catheterisation, with 
associated problems of recurrent catheter encrustation and blockage experienced by 
approximately 50% of all long-term catheterised patients.  In this work we have 
exploited, for the first time, the reported pathogen-induced elevation of urine pH as a 
trigger for ‘intelligent’ antimicrobial release from novel hydrogel drug delivery 
systems of 2-hydroxyethyl methacrylate and vinyl-functionalised nalidixic acid 
derivatives, developed as candidate infection-resistant urinary catheter 
coatings.  Demonstrating up to 20-fold faster rates of drug release at pH 10, 
representing infected urine pH, than at pH 7, and achieving reductions of up to 96.5% 
in in vitro bacterial adherence, our paradigm of pH-responsive drug delivery, which 
requires no external manipulation, therefore represents a promising development 
towards the prevention of catheter-associated urinary tract infections (CAUTIs) in 
vivo. 
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Introduction 
The employment of biomaterials in diverse diagnostic and therapeutic applications 
has led to significant advances within the practice of modern medicine, (1)  however, 
clinical applicability is ultimately limited by their inherent susceptibility to bacterial 
colonisation.  As one of the most predominant biomaterial-associated infections, 
catheter-associated urinary tract infections (CAUTIs) deserve particular attention. (2)   
Complications primarily result from activity of the bacterial enzyme, urease, which is 
secreted by many urinary pathogens, of which Proteus mirabilis is the most notorious.  
The resulting urease-catalysed hydrolysis of urea into ammonia elevates urinary pH to 
reported values up to pH 9.1, thereby triggering precipitation of magnesium and 
ammonium phosphate crystals. (3)   Complications, including crystalline biofilm 
formation, catheter encrustation and blockage, are experienced on a recurrent basis by 
approximately 50% of all long-term catheterised patients. (4)    
Complete eradication of biomaterial-associated infections is difficult due to 
the recalcitrance of bacteria in the biofilm-mode of growth, therefore much emphasis 
has now been placed on preventing infections by modification of the device to resist 
bacterial attachment.  Strategies investigated to-date include functionalisation of the 
surface with bacteria-repelling polymer brushes, (5) use of bioinert multilayer 
polymer coatings (6) and loading the device with antibacterial agents.  Passive, 
diffusion-controlled release of drug from the matrix interior of currently marketed 
antimicrobial biomaterials represents a suboptimal release strategy.  The antimicrobial 
lifetime of the device is restricted by an initial burst of surface-localised agent, which 
is thereafter followed by continuous drug elution in subtherapeutic levels, potentially 
promoting the emergence of bacterial resistance. (7)   One strategy to control release 
kinetics and ultimately achieve tailored drug delivery with a precise ‘on-off’ response, 
(8)  while also mitigating the compromise in mechanical properties associated with 
particulate release from the matrix interior, (9)  involves the application of labile drug 
conjugates to three-dimensional drug delivery systems. (10, 11)  
We have recently described the synthesis and pH-responsive release kinetics 
of a suite of novel, polymerisable drug conjugates containing the quinolone 
antimicrobial agent, nalidixic acid, covalently conjugated via hydrolytically labile 
ester bonds to alkenyl spacer moieties of varying vinyl chain lengths. (12)   Of 
particular significance towards the development of pH-responsive, infection-resistant 
urinary biomaterials is the faster hydrolysis and subsequent release of nalidixic acid 
from these conjugates at rates up to 17-fold greater at pH 9.29 than at pH 7.  These 
ester derivatives of nalidixic acid were herein copolymerised, for the first time, with 
2-hydroxyethyl methacrylate (2-HEMA), employing ethyleneglycol-dimethacrylate 
(EGDMA) as a crosslinker, to develop three-dimensional chemically-triggered drug 
delivery systems.  Characterisation of the synthesised copolymers in terms of water 
wettability, swelling characteristics, pH-mediated release kinetics, and resistance to 
adherence of P. mirabilis and Staphylococcus aureus informs the use of these drug 
conjugate-HEMA copolymers as infection-resistant catheter coatings capable of 
exploiting the elevation of urine pH reported at the onset of CAUTIs by urease-
producing urinary pathogens to trigger release of the conjugated antimicrobial agent, 
specifically through controlled ester hydrolysis.  
 
 
 
 
 
Experimental Section 
Materials  
Polymerisable ester nalidixic acid conjugates: 1-ethyl-7-methyl-4-oxo-1,4-dihydro-
1,8-naphthyridine-3-carboxylic acid 2-propen-1-ol ester 1, 1-ethyl-7-methyl-4-oxo-
1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 3-buten-1-ol ester 2, and 1-ethyl-7-
methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 9-decen-1-ol ester 3, 
the molecular structures of which are displayed in Figure 1, were synthesised as 
previously described. (12)  
2-Hydroxyethyl methacrylate (2-HEMA), ethyleneglycol-dimethacrylate 
(EGDMA), phosphoric acid, acetic acid, boric acid, hydrochloric acid, potassium 
chloride and sodium hydroxide were purchased from Sigma-Aldrich (Poole, Dorset, 
UK).  2,2'-Azobisisobutyronitrile (AIBN) was obtained from VWR International Ltd. 
(Lutterworth, UK).  Phosphate-buffered saline (PBS), tryptone soya broth (TSB), 
quarter-strength Ringer’s solution (QSRS) and Mueller-Hinton broth (MHB) were 
obtained from Oxoid Ltd (Hampshire, UK).  PBS and TSB were adjusted to pH 10 by 
addition of sodium hydroxide.  
Proteus mirabilis ATCC 35508 and Staphylococcus aureus ATCC 6538 (LGC 
Standards, Middlesex, UK) were maintained on cryopreservative beads (Protect 
Bacterial Preservation System, Technical Service Consultants Ltd., UK) in 10% 
glycerol at -80°C and cultivated in MHB at 37°C when required for the 
microbiological assessments.   
 
 
 
Figure 1: Molecular structures of polymerisable ester drug conjugates: 1-ethyl-7-
methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 2-propen-1-ol ester 1; 
1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 3-buten-1-ol 
ester 2; and 1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 
9-decen-1-ol ester 3. 
 
 
 
 
Methods 
Synthesis of Poly(2-Hydroxyethyl Methacrylate) (p(HEMA)) Homopolymers 
Films of p(HEMA) were synthesised, as previously described, (13)  by dissolving 
EGDMA (1% w/w) and AIBN (1% w/w) (crosslinker and initiator, respectively) at 
ambient temperature in 2-HEMA (98% w/w), with stirring.  The total mass of 
polymer was 10 g.  The resulting solution was injected slowly into moulds comprising 
two glass plates, which were separated with medical grade silicone tubing with lumen 
diameter of 0.3 mm and wall thickness of 0.18 mm, lined with release liner, and 
clamped using spring clips.  Following polymerisation at 90°C for a period of 3 h, the 
formed films were soaked for one week in deionised water to remove unreacted 
monomers and initiator, then dried to constant weight in an oven at 60°C to form 
xerogels.  The removal of all monomers from the films was verified by monitoring 
acrylate absorption in the rinsing media at 220 nm. 
 
Synthesis of Nalidixic Acid Conjugate-HEMA Copolymers 
Copolymers 4-6 were synthesised by stirring the respective conjugate from 1-3 (5% 
w/w) with EGDMA (1% w/w) and AIBN (1% w/w) at ambient temperature with 2-
HEMA (93% w/w).  The resulting solution was injected slowly into moulds, as 
described for p(HEMA), then polymerised at 90°C for one week.  In all cases, total 
copolymer mass was 10 g.  The formed copolymers were soaked for three weeks in 
deionised water to remove unreacted monomers. 
 
Contact Angle Analysis 
Sessile contact angles of the surfaces of the p(HEMA) homopolymer and the drug 
conjugate-HEMA copolymers 4-6 were determined using a First Ten Ångströms 
(FTA) 200 video-based contact angle analyser (Portsmouth, Virginia, USA) in 
conjunction with FTA 32 video software for image capture and analysis.  The tangent 
associated with a single drop of deionised water, used as the wetting medium, was 
measured in the equilibrium position on the sample surface. (14, 15)  
 
Equilibrium Swelling Studies 
The equilibrium degrees of swelling of p(HEMA) and the drug conjugate-HEMA 
copolymers 4-6 were examined in pH 7 universal buffer, prepared according to the 
formulation of Koller et al. (1992) (16)  reported in Table 1.  Replicate discs (1 cm2) 
were dried in an oven at 60°C until constant weight, weighed, and placed in pH 7 
universal buffer.  At designated intervals, discs were removed, blotted with filter 
paper to remove excess surface water, and reweighed, as previously described. (17)   
Discs were returned to the buffer media and soaked until no further change in mass.  
The weight percentage of buffer within the swollen polymer, designated as the 
equilibrium water content (EWC), was calculated according to the following equation 
(18) : 
 
EWC (%) = (Mf – Mi)/Mi x 100 
 
where Mf  and Mi  represent the final sample mass after water absorption and the 
initial dried sample mass respectively. 
 
 
 
Table 1: Formulation of Universal Buffer 
 
pH Stock 
(µL)a 
2 M 
NaOH 
(µL) 
KCl 
(mg) 
H2O 
(mL) 
7 833 437 25.8 11.43 
10 714 557 0 11.44 
aStock solution (100 mL) contained 2.7 mL H3PO4, 2.29 mL AcOH and 2.48 g H3BO3 
dissolved in deionised H2O. (16)  
 
In Vitro pH-Mediated Drug Release Kinetics 
Kinetics of nalidixic acid release from the drug conjugate-HEMA copolymers 4-6 
were examined at pH 7 and pH 10 in universal buffer solutions with constant ionic 
strength, prepared according to the formulation of Koller et al. (1992) (16)  reported 
in Table 1.  Pre-swollen copolymer discs (1 cm2), suspended on a needle, were placed 
in McCartney bottles containing 10 mL pre-warmed universal buffer solution of the 
appropriate pH and shaken at 37°C in an oscillating water bath (100 rpm).  At 
predetermined intervals, the discs were transferred to fresh media (10 mL, to ensure 
sink conditions) and the released drug quantified by UV-visible spectroscopy (λ = 
257 nm), with concentration dependence of nalidixic acid on absorbance determined 
from calibration curves prepared using universal buffer of the appropriate pH (r2 > 
0.999), as previously described. (19)   Release experiments at each pH were 
performed in quintuplicate. 
 
In Vitro Microbiological Analysis  
Bacterial suspensions of P. mirabilis and S. aureus (1 x 108 cfumL-1), in either PBS 
(pH 7) supplemented with 0.5% TSB (pH 7), or PBS (pH 10) supplemented with 1% 
TSB (pH 10), were diluted 1 in 100 with PBS containing 0.5% TSB of the required 
pH.  Replicate discs (8 mm) of copolymers 4-6 and p(HEMA) (as control) were cut 
from the polymer films, placed in individual wells of a 24-well flat bottom tissue 
culture plate (Corning Inc., Corning, NY), and completely immersed with aliquots of 
the bacterial suspension (1 mL) with density of 1 x 106 cfumL-1.  The plates were 
continuously shaken in an orbital incubator at 37°C.  After designated time intervals 
of 4 h and 24 h, the discs were removed from the bacterial suspension using sterile 
forceps, and non-adherent bacteria removed by washing for 30 sec in QSRS (3 x 5 
mL). (20)   The discs were transferred into fresh QSRS (5 mL), sonicated for 10 min, 
and vortexed for 30 s to remove adherent bacteria.  A viable count of the QSRS was 
performed by the Miles and Misra serial dilution technique, (21)  followed by plating 
onto low-swarm (LSW) agar (P. mirabilis) or Mueller-Hinton agar (S. aureus) to 
enumerate the previously adhered bacteria per disc.  The sonication technique has 
previously been demonstrated not to affect bacterial viability or morphology. (22)   
 
Statistical Analysis  
Statistical differences between the surface contact angles and equilibrium water 
contents of copolymers 4-6 and the p(HEMA) homopolymer were evaluated by a one-
way analysis of variance, whereas the effect of pH and conjugate alkyl chain length 
on the cumulative amounts of nalidixic acid released at designated intervals, and the 
effect of pH and copolymerisation with the ester drug conjugates on bacterial 
adherence after 4 h and 24 h were statistically evaluated by a two-way analysis of 
variance, followed by Tukey’s honestly significant difference test for post-hoc 
comparisons between means of individual groups.  In all cases, differences were 
considered significant when p < 0.05. (23)  
 
 
Results and Discussion 
The effect of copolymerisation with the drug conjugates on surface wettability and 
swelling characteristics was herein examined to assess changes in surface 
hydrophilicity/hydrophobicity and resulting water contents. These surface properties 
not only play a role in controlling rates of drug release, but are also involved in 
determining ultimate device performance in vivo. Application of the synthesised 
copolymers as medical device coatings provides a useful mechanism of modifying 
surface properties to optimise resistance to bacterial colonisation, improve device 
biocompatibility and minimise frictional irritation during device insertion and 
removal, whilst retaining bulk mechanical properties. (10, 11)  
 
Contact Angle Analysis 
The water wettability of the nalidixic acid conjugate-HEMA copolymers 4-6, 
prepared from the respective conjugates 1-3 (5% w/w), 2-HEMA (93%), and 
EGDMA crosslinker (1% w/w), was assessed in comparison to the control p(HEMA) 
homopolymer by measuring the static contact angles of deionised water on the sample 
surfaces.  The contact angles measured for the materials are presented in Table 2. 
 
Table 2: Static Contact Angles of p(HEMA) and Nalidixic Acid Conjugate-HEMA 
Copolymers 
 
Polymer Contact Angle (°) 
(Mean ± S.D.) 
p(HEMA) 52.5 ± 3.86 
4 75.6 ± 3.44 
5 80.1 ± 3.25 
6 61.5 ± 2.63 
 
Copolymerisation with the ester drug conjugates 1-3 (5% w/w) caused a significant 
increase in surface contact angle relative to the p(HEMA) homopolymer, as reported 
in Table 2.  This observed reduction in water wettability of the material surfaces was 
most likely attributed to the partial replacement of hydrophilic OH groups of 
p(HEMA) with comparatively more hydrophobic CH moieties of the conjugate alkyl 
chains.  
In contrast to the expected effect of alkyl chain length on water wettability of 
the surface, (24)  post-hoc analysis herein revealed that the surface of the longer-chain 
conjugate copolymer 6 was significantly more hydrophilic, as inferred by the 
statistically lower contact angle (61.5°), than the surfaces of the shorter-chain 
conjugate copolymers 4 and 5 (75.6° and 80.1°, respectively).  This observation was 
related to the higher relative molecular mass of conjugate 3 and the resultant lower 
molar ratio of amphiphilic nalidixic moieties within copolymer 6 than within 
copolymers synthesised from conjugates 1 or 2.  Relative to p(HEMA), the surface of 
6 was consequentially modified to a lower extent than the surfaces of the shorter-
chain conjugate copolymers 4 and 5.  In accordance with previous reports, (25)  
differences in the surface orientation of the amphiphilic nalidixic moiety, namely 
closer proximity to the surfaces of the short-chain conjugate copolymers 4 and 5 than 
the surface of copolymer 6, as a result of outward projection of this functional group 
by the longer alkyl chains of the latter, furthermore, contributed to the greater 
reduction in surface hydrophilicity observed with copolymers 4 and 5. 
 
Equilibrium Swelling Studies 
The equilibrium water contents (EWCs) of the drug conjugate-HEMA copolymers 4, 
5 and 6 in comparison to the p(HEMA) homopolymer, recorded after immersion in 
pH 7 universal buffer for 72 h, after which no further weight increase was recorded, 
are reported in Table 3.    
 
Table 3: Equilibrium Water Contents of p(HEMA) and Nalidixic Acid Conjugate-
HEMA Copolymers 
 
Polymer EWC 
(%) (± S.D.) 
p(HEMA) 75.6 ± 0.76 
4 74.0 ± 0.90 
5 75.1 ± 1.07 
6 70.3 ± 0.58 
 
Copolymer 6, synthesised from 2-HEMA and the longer-chain conjugate 3, displayed 
a statistically lower EWC than the p(HEMA) homopolymer and short-chain conjugate 
copolymers 4 and 5 (Table 3).  Polymer swelling is dependent on properties of the 
swelling medium, such as pH, temperature and ionic strength, and the polymer itself, 
such as the hydrophilic/hydrophobic balance, crosslink density and the presence of 
ionisable functional groups. (26)   In contrast to the constant universal buffer and 
degree of crosslinking (1% w/w), one factor that was comonomer-dependent and 
played a predominant role in the significant difference in EWC between p(HEMA) 
and copolymer 6 observed herein was the hydrophilic/hydrophobic balance of the 
polymer networks.  As previously reported, (27)  the more hydrophobic nature of the 
longer-chain conjugate 3 in comparison to 2-HEMA, 1 and 2 was responsible for 
reducing the overall polymer wettability and weakening the subsequent interactions 
between the copolymer network and the aqueous swelling medium.  In addition, chain 
entanglements of the long alkyl chain of conjugate 3 within the copolymer effectively 
interrupted relaxation of the polymer network and thereby reduced the resultant 
degree of swelling.   
 
In Vitro pH-Mediated Nalidixic Acid Release Kinetics 
The theory behind the development of these three-dimensional chemically-conjugated 
drug delivery systems as candidate infection-resistant catheter coatings is that upon 
elevation of urinary pH, hydrolysis of the ester bond linking nalidixic acid to the alkyl 
spacer moiety will be triggered with immediate effect, allowing free drug to 
effectively target biofilm bacteria at their fulcrum for adherence, before secretion of 
the protective glycocalyx.  To investigate the pH-responsive properties of these ester 
drug conjugate-HEMA copolymers, the rate of nalidixic acid release from copolymers 
4-6 was characterised as a function of pH.  Furthermore, the concept of tailoring rates 
of release via the employment of spacers of varying vinyl chain lengths was explored.  
Indwelling catheters may remain in situ for up to six weeks between scheduled 
changes, therefore release studies were continued for >42 days to assess ester bond 
stability during typical periods of device implantation.  The in vitro pH-mediated 
kinetics of nalidixic acid release from copolymers 4-6 are displayed in Figure 2.  
 
 
Figure 2: The effect of pH on the mean (± S.D.) release of nalidixic acid from 
copolymers 4, 5 and 6, represented by circles, squares and diamonds, respectively, at 
37°C with shaking.  Sink conditions were maintained throughout the study.  Open and 
closed symbols refer to release at pH 10 and pH 7 respectively.   
 
All copolymers displayed the same general trend in terms of release rate with respect 
to pH of the dissolution media.  The ester bond mediating attachment of nalidixic acid 
to the alkyl spacer moiety was relatively stable at normal physiological urine pH, pH 
7, (28, 29)  and therefore successfully delayed drug release from the copolymers, in 
contrast to the significantly more rapid rates of release demonstrated at the elevated 
pH typical of CAUTIs, pH 10, as shown in Figure 2.  This strategy is therefore of 
major applicability towards the development of infection-responsive urinary catheter 
coatings.  As a representative example, cumulative release of nalidixic acid after one 
week from copolymer 4 was 12-fold greater at pH 10 than at pH 7; cumulative 
amounts of nalidixic acid released were 24.6% and 1.99%, respectively.  We have 
previously reported the rapid diffusion-controlled release of nalidixic acid from 
physically-loaded p(HEMA) matrices, where more than 90% of the loaded nalidixic 
acid was released from the hydrogels within one hour of immersion in media of pH 7 
and pH 9. (13)   Release of nalidixic acid from the synthesised copolymers described 
herein, in contrast, approximated 80% after six weeks in media of pH 10, confirming 
the mechanism of release as hydrolysis-controlled.  The increase in release kinetics as 
the concentration of hydroxide ions increased was attributed to basic catalysis of the 
hydrolysis reaction, as previously reported. (30)  
In addition to environmental conditions, hydrolysis of polymer-drug 
conjugates is dependent on factors such as the nature and stability of the hydrolysable 
bond, the physical and chemical composition of the polymer, and steric overcrowding 
at the cleavage site, (31)  however, conflicting reports regarding the relative 
importance of these factors are found. (32, 33)   Of particular relevance to this in vitro 
study is the previously reported faster liberation of acyclovir, via ester hydrolysis, 
from polymer prodrugs with longer spacer moieties between the drug and the main 
polymer chain, attributed to the reduced steric hindrance for the incoming hydrolytic 
species. (34)   The effect of conjugate alkyl chain length on subsequent release 
kinetics in this study was, however, less evident, particularly in buffer of pH 10.  In 
contrast to the expected faster hydrolysis and subsequent release of nalidixic acid 
from the longer-chain conjugate copolymer 6 than from the shorter-chain conjugate 
copolymers 4 and 5, as was observed at pH 7 (cumulative release from copolymers 4, 
5 and 6 approximated 1.99%, 4.42% and 8.02% respectively after one week), 
cumulative amounts of nalidixic acid released from 6 were lower than from 4 and 5 
from day three onwards at pH 10, following release of the surface-localised nalidixic 
acid.  For example, after one week, cumulative release approximated 25.1%, 24.6% 
and 19.8% from copolymers 4, 5 and 6, respectively.  Reduced significance of ester 
bond accessibility to rates of drug release in media of alkaline pH has previously been 
attributed to the higher ester reactivity at elevated pH. (30)   Furthermore, the 
comparatively lower rates of nalidixic acid release from copolymer 6 than from the 
shorter-chain conjugate copolymers 4 and 5 at pH 10 was a combined result of the 
more tortuous copolymer matrix and the associated increase in hydrophobicity within 
the vicinity of the ester bond upon employment of longer alkyl spacers, as has been 
previously reported. (10, 27)   
Importantly, to effectively prevent bacterial colonisation, concentrations of 
drug in the release phase must exceed those required for inhibitory and cidal effects 
against the respective pathogens. This was assessed by in vitro microbiological 
studies and is reported below. 
 
In Vitro Microbiological Analysis 
To establish the utility of these chemically-triggered drug delivery matrices as 
biofilm-resistant urinary catheter coatings, the efficacy of the copolymers in resisting 
adherence of P. mirabilis and S. aureus relative to the p(HEMA) homopolymer was 
assessed herein by challenging samples of 4, 5, 6 and p(HEMA) with inoculi of 1 x 
106 cfumL-1 in media of pH 7 and pH 10 over time periods of 4 h and 24 h.  
Adherence of P. mirabilis to the drug conjugate-HEMA copolymers relative to the 
control p(HEMA) homopolymer is displayed in Figure 3. 
 
Figure 3: Microbial adherence (%) of P. mirabilis to unmodified p(HEMA) and 
copolymers of 2-HEMA and conjugates 1, 2 and 3, relative to the p(HEMA) 
homopolymer, denoted control, after 4 h and 24 h incubation at 37°C in media of pH 
7 (black) and pH 10 (grey).  Columns and error bars represent means ± S.E. (n = 5). 
 
The greatest reductions in bacterial adherence relative to the p(HEMA) control were 
achieved by copolymer 6 in media of pH 7, with adherence reduced by mean values 
of 70.9% and 78.9% after 4 h and 24 h, respectively (Figure 3).  Critical 
concentrations of nalidixic acid required for inhibitory and cidal effects against P. 
mirabilis have previously been determined as 9.38 mgL-1 and 37.50 mgL-1 (pH 7), 
and 26.04 mgL-1 and 83.33 mgL-1 (pH 10), respectively.  Consequential to the low 
initial loading of the drug conjugate monomers, the mean concentrations of nalidixic 
acid released from discs (1 cm2) of 4, 5 and 6 in pH 7 buffer after 24 h were 0.29 
mgL-1, 0.50 mgL-1 and 2.23 mgL-1, respectively.  Furthermore, in pH 10 buffer, when 
release was most rapid, cumulative release was again too low: mean concentrations of 
nalidixic acid were 1.59 mgL-1, 1.59 mgL-1 and 6.75 mgL-1 after 24 h incubation of 
discs (1 cm2) of 4, 5 and 6, respectively.  In vivo, however, concentrations are 
dependent on the site of implantation; in contrast to the relatively high urinary 
turnover rates experienced by ureteral stents as a result of the constant flow of urine 
from the kidneys, Foley catheters are subjected to comparatively lower turnover rates.  
Moreover, the retention balloon and the section of catheter immediately above the 
balloon reside within the bladder and are consequentially exposed to an essentially 
stagnant pool of urine. (35)   
The differences in bacterial adherence observed, for example, between 
copolymer 6 and the p(HEMA) control were therefore caused by changes in the 
physicochemical properties of the material surface, namely the reduction in surface 
wettability after copolymerisation with conjugate 3 in combination with the outward 
projection of the alkyl chains of 3 away from the copolymer surface, which ultimately 
make the surface less attractive to bacterial attachment. 
The comparative resistances of the nalidixic acid conjugate-HEMA copolymer 
and p(HEMA) homopolymer surfaces to adherence of S. aureus at pH 7 and pH 10 
are displayed in Figure 4. 
 
 
 
Figure 4:  Microbial adherence (%) of S. aureus after 4 h and 24 h to unmodified 
p(HEMA) and copolymers of 2-HEMA and conjugates 1, 2 and 3, relative to the 
p(HEMA) homopolymer, denoted control, after 4 h and 24 h incubation at 37°C in 
media of pH 7 (black) and pH 10 (grey).  Columns and error bars represent means ± 
S.E. (n = 5). 
 
After 4 h contact with the S. aureus challenge, significant reductions in bacterial 
adherence to copolymer 6 relative to the p(HEMA) homopolymer were demonstrated, 
irrespective of pH, with adherence reduced by mean values of 77.8% and 66.3% at pH 
7 and pH 10, respectively.  These significant reductions in bacterial adherence to 
copolymer 6 relative to the p(HEMA) homopolymer were maintained after 24 h 
contact with the bacterial challenge.  Bacterial adherence to copolymer 4 after 24 h in 
pH 10 media was also significantly reduced relative to the p(HEMA) homopolymers 
suspended in pH 7 and pH 10 media. 
Again these differences in bacterial adherence to the copolymers relative to 
the p(HEMA) control were attributed to factors other than the bacteriostatic or 
bactericidal activities of nalidixic acid due to the low amounts of nalidixic acid 
released from the copolymers and the well-established poor activity of this quinolone 
antibacterial agent against Staphylococci spp..  MIC values of nalidixic acid against S. 
aureus have previously been determined as 23 mgL-1 and 1000 mgL-1 at pH 7 and pH 
10, respectively, whereas no cidal activity was demonstrated against this isolate at 
either pH value when concentrations up to 2000 mgL-1 were tested. The observed 
reductions in bacterial adherence were therefore again attributed to changes in surface 
wettability and the presence of surface-localised alkyl chains following 
copolymerisation with the respective drug conjugates. 
Despite a low initial conjugate loading of 5% w/w within the copolymer, an 
encouraging, greater than one-logarithmic reduction in adherence of S. aureus was 
achieved by copolymer 6 relative to the p(HEMA) control after 24 h in pH 10 media.  
Tuning of the drug conjugate loading within the copolymers to promote greater 
release of nalidixic acid from the surface is therefore expected to ultimately enhance 
the efficacy of the synthesised copolymers in resisting bacterial adherence relative to 
unmodified p(HEMA). 
 
 
Conclusions 
The smart polymeric prodrug matrices developed herein as candidate infection-
responsive drug delivery systems are capable of releasing antimicrobial agents 
specifically, and rapidly, upon elevation of pH to values typically reported at the onset 
of urinary catheter infections.  All nalidixic acid conjugate-HEMA copolymers clearly 
demonstrate triggered release profiles with negligible release at pH 7, in the absence 
of urease-producing pathogens, and up to 20-fold faster rates of release upon 
elevation of pH to pH 10, as occurs in vivo due to the urease-catalysed hydrolysis of 
urea to ammonia.  Initial microbiological assessment of copolymers containing a 5% 
w/w loading of drug conjugate suggests that application of the conjugate-HEMA 
copolymers as urinary catheter coatings is a promising strategy towards the 
prevention of CAUTIs in vivo. 
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